Thank you, healthcare workers, for all you do. Your determination to help others is truly inspiring. Please stay safe.
Biologics in the Treatment of Adults With T2-High, Uncontrolled Asthma
Med-IQ Express Med-IQ Express

Biologics in the Treatment of Adults With T2-High, Uncontrolled Asthma


This activity was developed by Med-IQ in collaboration with Duke Health.

Med-IQ      Duke Medicine
 

Released:
4/20/2020
Expires:
4/19/2021

Maximum Credits:

0.25
By clicking "Continue," you confirm that you have reviewed the CME information.

Med-IQ Express Med-IQ Express
By clicking "Continue," you confirm that you have reviewed the CME information.
Released:
4/20/2020

Expires:
4/19/2021

Maximum Credits:
0.25
Med-IQ Express Med-IQ Express
By clicking "Continue," you confirm that you have reviewed the CME information.

Released:
4/20/2020
Expires:
4/19/2021


Maximum Credits:
0.25


Overview: This 15-minute publication discusses United States Food and Drug Administration (US FDA)-approved biologics used in the treatment of T2-high, uncontrolled asthma and features video-based commentary from an expert faculty member on how biologics have changed the treatment landscape for adults with asthma.

CME Information:

Faculty
Patricia Lugar, MD, MS 
Associate Professor of Medicine 
Chief, Section of Allergy and Immunology 
Medical Director, Medication Desensitization Program 
Duke Asthma, Allergy and Airway Center 
Department of Medicine 
Division of Pulmonary, Allergy and Critical Care 
Duke University School of Medicine 
Durham, NC 
 
Activity Planners
Stephanie Larson, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD

Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD

Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD

Amy Sison
CME Director
Med-IQ
Baltimore, MD 
 
Writer
Caitlin Rothermel, MA, MPH 
MedLitera   
Vashon, WA 
 
Learning Objectives
Upon completion, participants should be able to:

  • Identify FDA-approved biologics used in the treatment of adults with uncontrolled asthma  

Target Audience
This activity is intended for pulmonologists. 
 
Statement of Need
Asthma is a chronic airway disease that is associated with symptoms that range from mild to severe and uncontrolled. Even with the use of appropriate therapy, 10% to 20% of patients develop uncontrolled asthma, which is associated with a lower quality of life and a greater risk of death compared with patients who have well-controlled disease. The type 2 (T2)-high endotype is present in approximately 50% of patients with asthma and may be more prevalent in patients with severe disease. The FDA has approved several biologic agents that target the inflammatory pathways associated with T2-high asthma, and clinical trial data show that these biologics can decrease asthma exacerbations, improve symptoms, and/or reduce the use of oral corticosteroids in select patients with T2-high, moderate-to-severe, uncontrolled asthma. It is important that pulmonologists be familiar with biologic therapies that may significantly improve the quality of life of patients with T2-high, uncontrolled asthma.  

Collaboration Statement
This activity was developed by Med-IQ in collaboration with Duke Health.
 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: April 20, 2020
Expiration Date: April 19, 2021
Estimated Time to Complete This Activity: 15 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Patricia Lugar, MD, MS 
Consulting fees/advisory boards: CSL Behring, Takeda Pharmaceuticals North America, Inc. 
Contracted research: BioCryst Pharmaceuticals, Inc., CSL Behring, Takeda Pharmaceuticals North America, Inc.  
 
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
 
Copyright
© 2020 Duke University Health System

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.